Biotech Values

[dewophile]

So what these results are saying is that usually the drug does not work, but when it does work it works fairly decently.

with ovarian Ca usually RR are high, even with relapsed dx, but duration of response is short (pretty much everyone recurs). So this is just the opposite of what you see with chemo. MRK is now looking at combination chemo and PD-1 in ovarian Ca which makes sense

I've always worried that blocking MET is potentially double-edged

Perahps just an oversight - this trial didn't look at a MET blocker, just keytruda monotherapy